{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:22:53Z","timestamp":1789993373140,"version":"4.0.1"},"reference-count":50,"publisher":"Informa UK Limited","issue":"6","funder":[{"DOI":"10.13039\/501100023331","name":"Leo Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1080\/09546634.2016.1178372","type":"journal-article","created":{"date-parts":[[2016,5,10]],"date-time":"2016-05-10T03:57:36Z","timestamp":1462852656000},"page":"538-545","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Adherence to topical therapies in actinic keratosis: A literature review"],"prefix":"10.1080","volume":"27","author":[{"given":"Peter","family":"Foley","sequence":"first","affiliation":[{"name":",","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eggert","family":"Stockfleth","sequence":"additional","affiliation":[{"name":",","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Basset-Seguin","sequence":"additional","affiliation":[{"name":"Hopital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Cerio","sequence":"additional","affiliation":[{"name":",","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Antonio Sanches","sequence":"additional","affiliation":[{"name":"Departamento de Dermatologia, Universidade de Sao Paulo, Sao Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Guillen","sequence":"additional","affiliation":[{"name":"Instituto Valenciano de Oncologia, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Farrington","sequence":"additional","affiliation":[{"name":"Adelphi Values, Bollington, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,5,10]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"Stockfleth E Terhorst D Braathen L et\u00a0al. Guidelines for the management of actinic keratosis. 2010. Available from http:\/\/www.ensas.ee\/docs\/management_of_actinic_keratoses.pdf. Accessed November 2014."},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S9910"},{"key":"e_1_3_4_4_1","first-page":"651","article-title":"Development of a treatment algorithm for actinic keratoses: a European Consensus.","volume":"18","author":"Stockfleth E","year":"2008","unstructured":"Stockfleth E, Ferrandiz C, Grob JJ, et\u00a0al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol. 2008;18:651\u20139.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<920::AID-CNCR8>3.0.CO;2-F"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91658-3"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1998.00467.x"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00048.x"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12102"},{"key":"e_1_3_4_10_1","first-page":"1045","article-title":"Frequency and cost of actinic keratosis treatment.","volume":"32","author":"Warino L","year":"2006","unstructured":"Warino L, Tusa M, Camacho F, et\u00a0al. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006;32:1045\u20139.","journal-title":"Dermatol Surg"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S28905"},{"key":"e_1_3_4_12_1","first-page":"599","article-title":"Guidelines for the management of actinic keratoses.","volume":"16","author":"Stockfleth E","year":"2006","unstructured":"Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006;16:599\u2013606.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S31930"},{"key":"e_1_3_4_14_1","unstructured":"National Health Service. Skin cancer (non-melanoma). 2014. Available from http:\/\/www.nhs.uk\/conditions\/Cancer-of-the-skin\/Pages\/Introduction.aspx. Accessed January 2014."},{"key":"e_1_3_4_15_1","first-page":"335","article-title":"Actinic keratosis: how to differentiate the good from the bad ones?","volume":"16","author":"Quaedvlieg P","year":"2006","unstructured":"Quaedvlieg P, Tirsi E, Thissen M, Krekels G. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16:335\u20139.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24284"},{"key":"e_1_3_4_17_1","first-page":"201","article-title":"Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications.","volume":"87","author":"Feldman SR","year":"2011","unstructured":"Feldman SR, Fleischer Jr AB. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011;87:201\u20137.","journal-title":"Cutis"},{"key":"e_1_3_4_18_1","unstructured":"electronic Medicines Compendium (eMC). Summary of product characteristics for Aldara 5% cream. 2010. Available from http:\/\/www.medicines.org.uk\/emc\/medicine\/8\/spc. Accessed November 2014."},{"key":"e_1_3_4_19_1","unstructured":"electronic Medicines Compendium (eMC). Summary of product characteristics for Solaraze 3% gel. 2012. Available from https:\/\/www.medicines.org.uk\/emc\/medicine\/21229. Accessed November 2014."},{"key":"e_1_3_4_20_1","unstructured":"electronic Medicines Compendium (eMC). Summary of product characteristics for Zyclara 3.75% cream. 2013. Available from http:\/\/www.medicines.org.uk\/emc\/medicine\/27323. Accessed November 2014."},{"key":"e_1_3_4_21_1","unstructured":"electronic Medicines Compendium (eMC). Summary of product characteristics for Efudix cream. 2014. Available from http:\/\/www.medicines.org.uk\/emc\/medicine\/6219\/SPC\/Efudix+Cream. Accessed November 2014."},{"key":"e_1_3_4_22_1","unstructured":"electronic Medicines Compendium (eMC). Summary of product characteristics for Actikerall 5\u2009mg\/g + 100\u2009mg\/g cutaneous solution. 2014. Available from https:\/\/www.medicines.org.uk\/emc\/medicine\/24614. Accessed November 2014."},{"key":"e_1_3_4_23_1","unstructured":"electronic Medicines Compendium (eMC). Summary of product characteristics for Picato 500\u2009mcg\/g gel. 2013. Available from https:\/\/www.medicines.org.uk\/emc\/medicine\/27247. Accessed November 2014."},{"key":"e_1_3_4_24_1","unstructured":"electronic Medicines Compendium (eMC). Summary of product characteristics for Picato 150\u2009mcg\/g gel. 2014. Available from http:\/\/www.medicines.org.uk\/emc\/medicine\/27290. Accessed November 2014."},{"key":"e_1_3_4_25_1","unstructured":"Food and Drug Adminstration. Labelling revision for Efudex. 2005. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/016831s049lbl.pdf. Accessed February 2015."},{"key":"e_1_3_4_26_1","unstructured":"Food and Drug Adminstration. Labelling revision for Solaraze gel. 2011. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021005s013lbl.pdf. Accessed February 2015."},{"key":"e_1_3_4_27_1","unstructured":"Food and Drug Adminstration. Full prescribing information for Aldara. 2010. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020723s022lbl.pdf. Accessed February 2015."},{"key":"e_1_3_4_28_1","unstructured":"Food and Drug Adminstration. Full prescribing information for Zyclara. 2012. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022483s006lbl.pdf. Accessed February 2015."},{"key":"e_1_3_4_29_1","unstructured":"Food and Drug Adminstration. Full prescribing information for Picato. 2012. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202833lbl.pdf. Accessed February 2015."},{"key":"e_1_3_4_30_1","unstructured":"Food and Drug Adminstration. Labelling revision for Carac. 2003. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/20985slr004_carac_lbl.pdf. Accessed February 2015."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.757285"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.05776.x"},{"key":"e_1_3_4_33_1","doi-asserted-by":"crossref","unstructured":"Erntoft S Norlin J Pollard C Diepgen TL. Patient adherence and non-persistence behaviour in real life Actinic Keratosis (AK) topical treatment in the UK Germany and France. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research; 2014; Montreal.","DOI":"10.1016\/j.jval.2014.03.1672"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S47126"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2008.562"},{"key":"e_1_3_4_36_1","first-page":"335","article-title":"Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis.","volume":"70","author":"Jorizzo J","year":"2002","unstructured":"Jorizzo J, Stewart D, Bucko A, et\u00a0al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335\u20139.","journal-title":"Cutis"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.010"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111170"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04561.x"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.004"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01324.x"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04167.x"},{"key":"e_1_3_4_43_1","doi-asserted-by":"crossref","first-page":"A254","DOI":"10.1016\/j.jval.2012.03.1369","article-title":"Actinic keratosis patients are willing to pay for shorter treatment and local skin response duration and ingenol mebutate gel is likely to increase patient likelihood of successful completion of topical treatment.","volume":"15","author":"Willis M","year":"2012","unstructured":"Willis M, Erntoft S, Persson S, et\u00a0al. Actinic keratosis patients are willing to pay for shorter treatment and local skin response duration and ingenol mebutate gel is likely to increase patient likelihood of successful completion of topical treatment. Value Health. 2012;15:A254.","journal-title":"Value Health"},{"key":"e_1_3_4_44_1","first-page":"193","article-title":"Physicians\u2019 concerns towards prescription adherence and treatment effectiveness in the clinical management of actinic keratosis.","volume":"149","author":"Peris K","year":"2014","unstructured":"Peris K, Neri L, Fargnoli MC, Pellacani G. Physicians\u2019 concerns towards prescription adherence and treatment effectiveness in the clinical management of actinic keratosis. G Ital Dermatol Venereol. 2014;149:193\u20138.","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12530"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"e_1_3_4_47_1","volume-title":"Adherence to Long-term Therapies: Evidence for Action","author":"Sabat\u00e9 E.","year":"2003","unstructured":"Sabat\u00e9 E. Adherence to Long-term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003."},{"key":"e_1_3_4_48_1","first-page":"22","article-title":"Considerations for use of fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients.","volume":"1","author":"Werschler WP.","year":"2008","unstructured":"Werschler WP. Considerations for use of fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients. J Clin Aesthet Dermatol. 2008;1:22.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0104"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08271.x"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12475"}],"container-title":["Journal of Dermatological Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09546634.2016.1178372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:11:46Z","timestamp":1772701906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546634.2016.1178372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,10]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1080\/09546634.2016.1178372"],"URL":"https:\/\/doi.org\/10.1080\/09546634.2016.1178372","relation":{},"ISSN":["0954-6634","1471-1753"],"issn-type":[{"value":"0954-6634","type":"print"},{"value":"1471-1753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}